Prosecution Insights
Prosecution Insights
6 pending office actions • 3 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (33%) |
| §112 only | 2 (33%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ROONEY, NORA MAUREEN | 1 | 60.2% | +23.8% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| GZYBOWSKI, MICHAEL STANLEY | 1 | 67.3% | +53.5% |
| JOHANSEN, PETER N. | 1 | 58.9% | +24.3% |
| LU, CHENG | 1 | 53.7% | +66.2% |
| GUSTILO, ESTELLA M | 1 | 53.2% | +36.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18282767 | A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF | JOHANSEN, PETER N. | 21d |
| 18952889 | NOVEL ANTI-PD-L1 ANTIBODIES | ROONEY, NORA MAUREEN | — |
| 18692311 | D3-BINDING MOLECULES AND USES THEREOF | OUSPENSKI, ILIA I | — |
| 18292279 | SYSTEM FOR EXPRESSION, PURIFICATION, AND DETECTION AND SCREENING OF BIOLOGICAL DRUGS | GZYBOWSKI, MICHAEL STANLEY | — |
| 18270160 | MULTISPECIFIC ANTIGEN BINDING PROTEINS | LU, CHENG | — |
| 17425870 | NOVEL BISPECIFIC CD3/CD20 POLYPEPTIDE COMPLEXES | GUSTILO, ESTELLA M | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1642 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18952889 | NOVEL ANTI-PD-L1 ANTIBODIES | ROONEY, NORA MAUREEN | — | §112Other | Non-Final OA | — | Pending | Nov 19, 2024 |
| 18692311 | D3-BINDING MOLECULES AND USES THEREOF | OUSPENSKI, ILIA I | — | §112 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18292279 | SYSTEM FOR EXPRESSION, PURIFICATION, AND DETECTION AND SCREENING OF BIOLOGICAL DRUGS | GZYBOWSKI, MICHAEL STANLEY | — | §103 | Non-Final OA | — | Pending | Jan 25, 2024 |
| 18282767 | A BISPECIFIC ANTI-PD-L1/VEGF ANTIBODY AND USES THEREOF | JOHANSEN, PETER N. | 1644 | §103 | Final Rejection | 21d | Pending | Sep 18, 2023 |
| 18270160 | MULTISPECIFIC ANTIGEN BINDING PROTEINS | LU, CHENG | 1642 | §102§103§112DP | Non-Final OA | — | Pending | Jun 28, 2023 |
| 17425870 | NOVEL BISPECIFIC CD3/CD20 POLYPEPTIDE COMPLEXES | GUSTILO, ESTELLA M | 1646 | DP | Non-Final OA | — | Pending | Jul 26, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial